Wall Street brokerages expect Endo International PLC (NASDAQ:ENDP) to report earnings of $0.73 per share for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Endo International PLC’s earnings, with the lowest EPS estimate coming in at $0.65 and the highest estimate coming in at $0.81. Endo International PLC posted earnings of $0.86 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 15.1%. The firm is scheduled to announce its next quarterly earnings results before the market opens on Tuesday, August 8th.
On average, analysts expect that Endo International PLC will report full-year earnings of $3.61 per share for the current financial year, with EPS estimates ranging from $3.45 to $3.73. For the next financial year, analysts forecast that the company will report earnings of $3.46 per share, with EPS estimates ranging from $3.02 to $3.80. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Endo International PLC.
Endo International PLC (NASDAQ:ENDP) last issued its quarterly earnings results on Tuesday, May 9th. The company reported $1.23 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.10 by $0.13. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. Endo International PLC had a negative net margin of 82.93% and a positive return on equity of 25.32%. The firm’s quarterly revenue was up 7.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.08 EPS.
Several brokerages have issued reports on ENDP. Guggenheim began coverage on Endo International PLC in a research report on Saturday, June 17th. They issued a “hold” rating and a $12.00 target price on the stock. Deutsche Bank AG dropped their target price on Endo International PLC from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, July 7th. Royal Bank Of Canada set a $15.00 price objective on Endo International PLC and gave the company a “hold” rating in a research report on Saturday, April 8th. Zacks Investment Research cut Endo International PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, Canaccord Genuity set a $12.00 price objective on Endo International PLC and gave the company a “hold” rating in a research report on Thursday, June 8th. Three equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $17.33.
Shares of Endo International PLC (NASDAQ ENDP) traded down 1.87% during trading on Tuesday, hitting $12.06. 3,229,153 shares of the company were exchanged. Endo International PLC has a 1-year low of $9.70 and a 1-year high of $24.93. The company has a 50 day moving average of $11.78 and a 200-day moving average of $12.04. The stock’s market capitalization is $2.69 billion.
Several large investors have recently modified their holdings of ENDP. Amalgamated Bank raised its position in shares of Endo International PLC by 2.0% in the first quarter. Amalgamated Bank now owns 32,357 shares of the company’s stock valued at $361,000 after buying an additional 619 shares in the last quarter. Meeder Asset Management Inc. raised its position in shares of Endo International PLC by 1.4% in the second quarter. Meeder Asset Management Inc. now owns 48,699 shares of the company’s stock valued at $544,000 after buying an additional 677 shares in the last quarter. Capstone Asset Management Co. raised its position in shares of Endo International PLC by 3.1% in the second quarter. Capstone Asset Management Co. now owns 32,035 shares of the company’s stock valued at $358,000 after buying an additional 960 shares in the last quarter. Point View Wealth Management Inc. raised its position in shares of Endo International PLC by 12.3% in the first quarter. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock valued at $128,000 after buying an additional 1,254 shares in the last quarter. Finally, Jensen Investment Management Inc. raised its position in shares of Endo International PLC by 5.8% in the first quarter. Jensen Investment Management Inc. now owns 24,660 shares of the company’s stock valued at $275,000 after buying an additional 1,360 shares in the last quarter. Institutional investors and hedge funds own 93.17% of the company’s stock.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Get a free copy of the Zacks research report on Endo International PLC (ENDP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.
